For the latest updates on Gilead’s ongoing response to COVID-19, please click here.
Kite Announces U.S. FDA Clearance of Investigational New Drug Application for KITE-222, an Anti-CLL-1 CAR T-Cell Therapy Candidate for Acute Myeloid Leukemia